tirzepatide cause high blood pressure Effects of tirzepatide, a dual GIP and GLP-1 receptor agonist, on pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats The Cardiovascular Effect of Tirzepatide:

The SELECT trial showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in people with overweight or obesity and established cardiovascular disease, and benefits appeared early, before substantial weight loss had occurred

Helping young women go red: harnessing the power of personal and digital information to prevent heart disease

Real-world adherence is substantially lower than clinical-trial completion rates, with persistence estimates ranging from approximately one-third to one-half at 1 year and substantially lower by 2 years in many analyses

The gap between reliable vendors and unreliable ones is not small

The goal is not dependency on an external signal but restoration of internal regulation

Cell Physiol Biochem 44(2):532553